Nurix Therapeutics, Inc. $NRIX Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. boosted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 32.5% during the 4th quarter, Holdings Channel reports. The institutional investor owned 5,949,512 shares of the company’s stock after acquiring an additional 1,460,736 shares during the period. Vanguard Group Inc. owned approximately 0.08% of Nurix Therapeutics worth $112,862,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wexford Capital LP acquired a new stake in Nurix Therapeutics during the third quarter valued at $41,000. Mirae Asset Global Investments Co. Ltd. grew its position in Nurix Therapeutics by 66.6% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,926 shares of the company’s stock valued at $93,000 after buying an additional 1,970 shares during the period. Tower Research Capital LLC TRC grew its position in Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock valued at $73,000 after buying an additional 3,475 shares during the period. Sherbrooke Park Advisers LLC acquired a new stake in Nurix Therapeutics during the third quarter valued at $100,000. Finally, 49 Wealth Management LLC acquired a new stake in Nurix Therapeutics during the third quarter valued at $108,000.

Nurix Therapeutics Price Performance

NRIX stock opened at $15.96 on Wednesday. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $22.50. The firm has a market capitalization of $1.65 billion, a P/E ratio of -5.05 and a beta of 1.87. The business’s 50-day moving average is $15.90 and its two-hundred day moving average is $16.34.

Nurix Therapeutics (NASDAQ:NRIX) last released its earnings results on Wednesday, April 8th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.03). The firm had revenue of $6.25 million for the quarter, compared to analysts’ expectations of $14.25 million. Nurix Therapeutics had a negative return on equity of 64.21% and a negative net margin of 411.37%. On average, analysts expect that Nurix Therapeutics, Inc. will post -2.94 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently commented on NRIX. Needham & Company LLC restated a “buy” rating and set a $26.00 price target on shares of Nurix Therapeutics in a research report on Thursday, April 23rd. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Monday, April 27th. BTIG Research restated a “buy” rating and set a $30.00 price target on shares of Nurix Therapeutics in a research report on Thursday, January 29th. Weiss Ratings restated a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Tuesday, April 21st. Finally, Piper Sandler boosted their price target on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the stock an “overweight” rating in a research report on Thursday, January 29th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $30.46.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 14,055 shares of the business’s stock in a transaction on Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total transaction of $233,313.00. Following the completion of the transaction, the chief financial officer owned 37,592 shares in the company, valued at approximately $624,027.20. The trade was a 27.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Gwenn Hansen sold 3,214 shares of the stock in a transaction on Thursday, April 30th. The shares were sold at an average price of $16.65, for a total value of $53,513.10. Following the completion of the transaction, the insider directly owned 120,399 shares in the company, valued at $2,004,643.35. This trade represents a 2.60% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 19,657 shares of company stock valued at $326,586 in the last quarter. 6.70% of the stock is currently owned by company insiders.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.